Early access
Sign in
Taking people in United StatesNo phase

Tests a heart magnetic scan for detecting amyloidosis

Checks whether magnetocardiography can detect and track amyloidosis in adults compared with ECG.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
A Study Of MCG In Cardiac Amyloidosis
Status
Recruiting
People taking part
500 people, planned
Started
3 Dec 2025
Expected to end
Nov 2027
Type of study
Observational
Treatments tested
  • SandboxAQ CardiAQ Magnetocardiography
Record updated
22 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with amyloidosis who can have a heart magnetic scan (MCG) to test how well it finds and tracks the disease.

Age
18 years or older
Sex
All sexes can join.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Active atrial fibrillation episode on the latest 12-lead ECG
  • Active metal implants in the chest, such as a pacemaker, heart monitor or internal defibrillator
  • External pads or devices on the chest that must stay on during the MCG scan
  • Cannot lie down and stay still on the examination bed

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥ 18 years on the date of consent
  • Ability for participant to comply with study requirements
  • Written informed consent

Who cannot take part

  • Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator)
  • External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
  • Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
  • Pregnant or breastfeeding
  • Having an active atrial fibrillation episode as seen on most current 12-lead ECG
  • Inability to lie down in a supine/inclined position and stay still on the examination bed

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Structural Heart Research TeamTaking people

About the trial

What the trial wants to find out

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

The group in the trial

  • Patients with amyloidosis

    Treatment: SandboxAQ CardiAQ Magnetocardiography

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Study of Magnetocardiography for Disease Detection and Monitoring Treatment Outcomes in Amyloidosis
Plain-language title
Tests a heart magnetic scan for detecting amyloidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 December 2025